Wisconsin joins federal lawsuit against Hims & Hers over alleged privacy violations

Wisconsin joined a federal lawsuit against Hims & Hers, alleging the company shared customer health data with advertisers and misled consumers on billing. The suit seeks refunds, penalties, and an injunction. Wisconsin Attorney General Josh Kaul emphasized the importance of protecting sensitive health information. Other states and the FTC are also involved.

Original reporting
Published Nov 13, 2026, 5:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 5:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wisconsin joins federal lawsuit against Hims & Hers over alleged privacy violations — source image
Decision brief

The 30-second read

$HIMSBearishMed
01

Why it matters

The complaint seeks consumer refunds, financial penalties, and a permanent court order, which can translate into direct costs and operational changes to data-sharing and subscription management.

02

Market read

A multi-state and FTC-involved lawsuit increases compliance and litigation risk for Hims & Hers, which can affect valuation via expected legal costs and potential injunction risk.

03

What to watch

Investors may discount the case if prior disclosures and consent mechanisms are strong; also, settlement terms and the scope of any injunction are key unknowns not provided here.

Relevance 7/10Novelty 7/10Timing: new lawsuit filing update reported today

Background

Wisconsin is joining an existing enforcement effort that includes multiple states and the Federal Trade Commission, alleging privacy violations and misleading billing/subscription practices by Hims & Hers.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Wisconsin joined a federal lawsuit alleging Hims & Hers shared customers’ sensitive health data with advertisers like Meta and Snap and misled on billing.

Expected impact

Likely downward pressure as investors price higher legal/settlement and compliance costs and potential business-model constraints.

Evidence & confidence

The article describes an active, multi-state FTC-involved lawsuit seeking refunds, financial penalties, and a permanent injunction, which typically increases downside tail risk for the defendant.

Market effects

Heightens scrutiny of telehealth and direct-to-consumer healthcare platforms’ privacy, ad targeting, billing disclosures, and subscription cancellation flows.

Adds another state regulator to the enforcement coalition, increasing perceived likelihood of broader compliance changes.

Supports a wider trend of privacy enforcement that can affect cross-border ad targeting and health-data handling practices.

Counterpoint

The lawsuit may take time to resolve, and outcomes could be limited to specific practices rather than a broad injunction, reducing near-term earnings impact.

Key entities

  • Hims & Hers

    Online healthcare provider accused of sharing sensitive health information with advertisers and misleading consumers about billing and subscriptions.

  • Wisconsin Attorney General Josh Kaul

    Quoted emphasizing reliance on privacy representations for sensitive health information.

  • Federal Trade Commission

    Named as part of the legal action coalition.

  • Meta

    Named as an advertising platform allegedly receiving shared health data.

  • Snap

    Named as an advertising platform allegedly receiving shared health data.

Related articles

$HIMSMed

Canaccord reiterates Hims & Hers stock rating on peptide launch

Canaccord Genuity reiterated a Buy rating and $40 price target for Hims & Hers Health (HIMS) after its launch of Peptides+ treatment line. The company reported Q3 revenue of $890M, up 49% YoY, but saw a subscriber decline. Analysts have mixed views on its outlook, with some lowering price targets due to subscriber losses and others optimistic about future growth.

$HIMSHighAI 8/10

Should Hims & Hers Stock's Drop After Earnings Worry You?

Hims & Hers Health (HIMS) stock dropped 16.6% after reporting Q3 2026 earnings. Revenue of $890M missed estimates by 2.2%, and EPS was -$0.10 vs. expected $0.06 profit. Subscribers fell by 100,000 to 2.8M. Management cut full-year EBITDA and revenue forecasts, citing marketing adjustments and delayed revenue recognition.

$HIMSMed

Wisconsin joins federal lawsuit against Hims & Hers telehealth provider

Wisconsin joined a federal lawsuit against Hims & Hers Health, alleging the telehealth provider shared customer health data with Meta and Snapchat, and engaged in deceptive subscription practices. The state seeks an injunction and restitution. Hims denies wrongdoing, stating it provides clear information to customers. The FTC and six other states are also involved.

$HIMSHighAI 8/10

Hims & Hers Revenue Climbs 49% as Gross Margin Falls to 57%

Hims & Hers reported Q3 2026 revenue of $890.4M, up 49% YoY, but gross margin fell to 57% from 74%. Net loss was $33M vs. $15.8M net income a year ago. Adjusted EBITDA rose to $82.4M. The company forecasts Q4 revenue of $875M-$895M and full-year revenue of $3.13B-$3.15B, but lowered adjusted EBITDA guidance to $257M-$277M.